" class="no-js "lang="en-US"> Aurum South Africa - Medtech Alert
Saturday, August 02, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Aurum South Africa | Pharmtech Focus

Aurum South Africa

About Aurum South Africa

Aurum South Africa
The Aurum Institute is a proudly African, public-benefit organisation with over 21 years’ experience in leading the response, treatment and research efforts to eradicate TB and HIV. We have been working alongside government, the mining industry, among NGO’s and in communities to better understand global health challenges to provide real solutions.

Related Story

Clinical Trials

 IAVI and Moderna Launch First-in-Africa Clinical Trial of mRNA HIV Vaccine Development Program | Pharmtech Focus

IAVI and Moderna Launch First-in-Africa Clinical Trial of mRNA HIV Vaccine Development Program

May 20 2022

The nonprofit scientific research organization IAVI and Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger […]